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Our interest on BDNF started when we came across with the
publication by Boulanger and Poo [see 1] where it was shown that the
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neuromuscular junction is facilitated by depolarization [1]. It is well
known that depolarizing conditions are able to induce adenosine
release [2]. Since the distribution of adenosine A2A receptors (A2ARs)
and TrkB receptors (BDNF receptors) have a considerable overlap
[3,4], and considering that A2AR activation can induce TrkB phos-
phorylation in the absence of neurotrophins, a process known as
transactivation of TrkB receptors [5], the atmosphere was highly
propitious to further detail the consequences and the mechanisms
related to the cross-talk between A2AR and BDNF in neuronal cells.
However, as we will discuss below and recently suggested [6], it may
happen that A2AR-mediated TrkB receptor transactivation and A2AR-
mediated facilitation of BDNF actions at synapses constitute two
different, nevertheless related, processes through which adenosine
affects TrkB signalling. In this paper we will mostly focus on the
triggering of synaptic actions of BDNF by A2ARs and mechanisms
involved in it, but before we enter into this topic we will highlight
work that preceded and prompted this line of research.
1.1. Neurotrophins
The ﬁrst neurotrophin to be identiﬁed was the nerve growth factor
(NGF) in the 1950s by Rita Levi-Montalcini, Stanley Cohen and Viktor
Hamburger [7,8]. The neurotrophin family is composed by four
members: nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3)
and neurotrophin-4 (NT-4). They have been classically seen as key
regulators of neuronal differentiation, maturation and survival [9], but
neurotrophins also have an essential role as modulators of synaptic
transmission and plasticity [10–12]. It is now well known that BDNF
has presynaptic regulatory actions on synaptic transmission, inducing
an increase in the number of docked vesicles at the active zones [13],
as well as postsynaptic regulatory actions, which include modulation
of ionotropic glutamatergic [14] and cholinergic [15] receptors.
From the four neurotrophins cloned to date, the actions of BDNF
are the best characterized in the brain. BDNF is a 252 amino acid
protein present in many mammalian species with almost identical
sequences; BDNF synthesis is highly regulated and occurs primarily in
neurons. BDNF is not produced as a mature protein, but as
preproBDNF in the endoplasmic reticulum. When the signal peptide
is cleaved, proBDNF is formed; a great number of reports have now
established that proBDNF can be secreted by the cell and that it has
important biological activity [16]. Mature BDNF (mBDNF) can be
produced by cleavage of proBDNF intra or extracellularly, but the
precise sources and localization of mBDNF production are far from
being understood [17,18].
1.1.1. Neurotrophin receptors
Neurotrophins exert their biological actions through activation of
one of the two families of receptors [see, e.g.,10]: (1) the high afﬁnity
tropomyosin-related kinase receptors (Trk), which belong to the
tyrosine kinase family of receptors. There are three types of Trk
receptors: TrkA receptors, that speciﬁcally recognize NGF; TrkB
receptors, that bind both BDNF and NT-4 and TrkC receptors, speciﬁc
for NT-3; and (2) p75NTR receptors, which are single-transmembrane
proteins of the superfamily of tumor necrosis factor (TNF) receptors.
The p75NTR recognizes all neurotrophins with low afﬁnity, approxi-
mately 100-fold less than the Trk receptors. However, proneurotro-
phins bind with high afﬁnity to this class of receptors [19].
BDNF binds with high afﬁnity to TrkB receptors and induces
receptor dimerization and autophosphorylation. Following BDNF
binding to the TrkB receptor, multiple signalling cascades are
activated and this requires docking of several proteins to the
intracellular domain of full-length TrkB receptors (TrkB-FL) [10].
Essentially, BDNF-induced phosphorylation of TrkB receptors acti-
vates the PLCγ, Akt and MAPK pathways, but novel partners for TrkB
receptors have been reported and may contribute signiﬁcantly to theTrkB-mediated effects of BDNF [see e.g. 10]. The activation of the PLCγ
pathway has been more closely related to fast actions of BDNF, while
the Akt and MAPK pathways are usually associated with neuronal
survival pathways [20].
Alternative splicing of TrkB receptors leads to the formation of
truncated receptors, TrkB-T1, TrkB-T2 and TrkB-T-Shc [21,22], being
TrkB-T1 the best-studied isoform. TrkB-T1 receptors lack most of the
intracellular domain and, therefore, intrinsic catalytic activity [10,23].
Although the biological functions and signalling cascades activated by
TrkB-T1 remain elusive, there are reports showing that TrkB-T1
increases intracellular calcium and may play a role in dendritic
complexity of certain neurons [24]; additionally, TrkB-T1 may be seen
as a negativemodulator of TrkB-FL signaling, through sequestration of
BDNF molecules [25,26].
1.1.2. BDNF functions
In the nervous system, neurotrophins regulate the development,
maintenance and function of multiple neuronal networks [reviewed
in 9]. Mice lacking neurotrophins die usually 2–4 weeks after birth
[27–29], and heterozygous mice display functional deﬁcits in the
nervous system. For example, NGF+/− mice display memory deﬁcits
and loss of basal forebrain cholinergic neurons and peripheral neurons
[30,31]. BDNF−/−mice display severe alterations in coordination and
balance and degeneration in several sensory ganglia; BDNF+/− mice
are obese, develop hyperphagia and aggressiveness [32,33]. Addition-
ally, BDNF+/− mice have increased striatal dopamine levels that are
correlated with altered behavioral responses involving the nigros-
triatal dopaminergic system [34].
BDNF and TrkBmRNA are widely distributed in the central nervous
system (CNS) [35–37]. In addition to its well-known effects on the
regulation of neuronal survival, differentiation and growth, BDNF is
also able to modulate neurotransmitter release in different brain
areas. Presynaptic effects of BDNF on synaptic activity have been ﬁrst
demonstrated at the neuromuscular junction [38]. Other studies
established the role of BDNF in increasing the release of acetylcholine
and glutamate, both in the hippocampus and cerebral cortex [13,39–
42]. Effects on the GABAergic transmission have also been reported,
involving both presynaptic [43] and postsynaptic [44] actions, as well
as stimulatory effects of BDNF on dopamine release in mesencephalic
neurons [45].
The fast actions of BDNF at synapses can occur in a time scale of
less than 1 h, leading to facilitation of synaptic transmission [46,47].
These relatively fast synaptic actions of BDNF may require de novo
protein synthesis, as it has been shown to occur in relation to the
BDNF-induced increases in AMPA [48] and NMDA [49] receptor levels
in themembrane of cultured neurons. In addition, someof the synaptic
BDNF actions result from a local, very fast action at synapses; this
neurotrophin is able to facilitate glutamate release from synaptosomes
[42,50,51], which are isolated nerve endings and therefore lack the
somatic machinery for modulation at the gene transcription level.
The physiological role of endogenous BDNF in synaptic plasticity
has been clearly demonstrated in the BDNF-deﬁcient mice, where
long-term potentiation (LTP) was severely impaired [52,53]. While
mBDNF facilitates LTP through activation of TrkB receptors [54],
proBDNF facilitates long-term depression (LTD) through activation of
p75NTR receptors [55]. The control of proBDNF cleavage into BDNF is
regulated by activity. Low-frequency ﬁring induces LTD and favours
proBDNF actions, while high-frequency ﬁring induces LTP and favours
mBDNF actions in the hippocampus [56].
Furthermore, intense synaptic activity increases the levels of TrkB
mRNA and its translocation to dendrites [57,58], as well as TrkB
receptor insertion in the plasma membrane [59,60]. These activity-
dependent actions of BDNF may play an important role in the
regulation and speciﬁcity observed in BDNF actions upon active
synapses and may involve translocation of TrkB receptors to speciﬁc
membrane microdomains, as we will discuss in Section 2.5 below.
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The interest on neurotrophins in a context of neurodegenerative
diseases started soon after the discovery of NGF and the identiﬁcation
that this neurotrophin promotes the survival and function of basal
forebrain cholinergic neurons [61], which project to the hippocampus
and are speciﬁcally affected in patients with Alzheimer's disease (AD).
The identiﬁcation of other members of the neurotrophin family, like
BDNF, and the knowledge of its physiological functions, inspiredmany
studies [for a review see e.g. 62] correlating the pathogenesis of
human neurodegenerative disorders with alterations in BDNF actions.
These could be a result of genetic polymorphisms in the BDNF gene or
receptors, alterations in the levels of mRNA for BDNF, modiﬁcations in
levels of BDNF protein and changes in BDNF receptor densities.
A polymorphism in BDNF gene leading to a different BDNF protein
(BDNF Val66Met) appears to alter susceptibility to neuropsychiatric
disorders, such as AD [63], Parkinson's disease (PD) [64], depression
[65], and bipolar disorders [66,67]. In 1991, Phillips and colleagues [68]
reported a selective reduction of BDNF mRNA expression in the
hippocampus of individuals with AD, which was later corroborated by
others [69,70]. Moreover, a decrease in BDNF protein levels in the
hippocampus has been associated with depression [71,72]. Decreased
BDNF protein levels were also found in nigrostriatal dopamine-rich
regions of PD brains [73]. A decrease in the expression of the BDNF
protein in the hippocampus of people with dementia exhibiting Lewy
bodies [74] in patientswith diabetic brain neuropathies [75] and in the
striatum of individuals with Huntington's disease (HD) [see 76] was
also reported. BDNF levels are also severely affected in HD patients
[76].
Concerning modiﬁcations in TrkB receptors, a mutation in the
kinase domain of TrkB, leading to impaired intracellular signalling,was
associated with obesity and developmental delay [77]. On the other
hand, the expression of different TrkB splice variantsmay be related to
cognitive capacity, as overexpression of the kinase-containing form
enhances memory and learning in transgenic mice [78]; conversely,
overexpression of the TrkB-T1 isoform in adult neurons impairs long-
term memory [79]. Interestingly, increased content of the TrkB-T1
isoform and decreased TrkB expression has been observed in AD
patients [80]. Finally, polymorphisms of the gene encoding p75NTR
may lead to an increased susceptibility to depressive disorders [81].
1.2. Adenosine
Adenosine is a ubiquitous molecule that acts in a paracrine way,
i.e., in the cells adjacent to the adenosine-releasing cell, due to its
extremely short half-life [82]. Adenosine can be formed both intra and
extracellularly, and cross the plasmamembrane through equilibrative
(ENT) or concentrative transporters. Intracellular formation of
adenosine occurs mainly through two pathways: from the sequential
dephosphorylation of ATP or from the hydrolysis of S-adenosylho-
mocysteine [83]. Intracellular adenosine metabolism occurs mostly
through phosphorylation into AMP or through deamination to
inosine. Inactivation of extracellular adenosine predominantly occurs
through reuptake; however, metabolism of extracellular adenosine
through deamination to inosine or phosphorylation to 5'-adenosine
monophosphate (5'-AMP) [84] can also occur. Extracellular formation
of adenosine is due to hydrolysis of released adenine nucleotides,
namely ATP, through a cascade of ecto-nucleotidases [85]. In resting
conditions, the extracellular adenosine concentration in the brain are
around 25-250 nM [86], but those levels can increase dramatically
under energy misbalance [87]. For this reason, adenosine is described
as a retaliatory metabolite and plays an important role during seizure,
hypoxic and ischemic events, where it acts as a protective signal in the
nervous system [87–89]. Importantly, adenosine not only directly
modulates synaptic transmission and plasticity but alsomodulates the
actions of other neurotransmitters or modulators, such as neurotro-
phins, dopamine and cannabinoids [reviewed in 90].1.2.1. Adenosine receptors
Four adenosine receptors have been cloned to date: adenosine
A1, A2A, A2B and A3 receptors, all belonging to the superfamily of G-
protein coupled receptors (GPCRs). Adenosine A1 and A3 receptors are
mainly coupled to Gi proteins, while the A2A and A2B receptors act
mainly through activation of Gs proteins [91], though coupling to Gq
can also occur. A1 and A2A receptors are considered to be the high
afﬁnity receptors for adenosine, and in basal conditions are probably
tonically activated [86]. However, this should be considered carefully
sincemost cells expressmultiple adenosine receptors in very different
levels, limiting the study of native receptors behaviour in response to
the endogenous ligand adenosine.
In the brain, adenosine receptors are widely distributed, with
marked differences in receptor expression depending on the brain
area, age and cell sublocalization [92]. A1 receptors (A1R) are the
predominant subtype in the forebrain, cerebellum and dorsal horn of
spinal cord, while A2AR are highly expressed in the striatopallidal
GABAergic neurons and the olfactory bulb. Adenosine A2B and A3
receptors are also expressed in the brain, but their expression is
considerably more restricted and their role in the nervous system is
much less understood [see, e.g., 90,92]. Both A1 and A2A receptors can
be localized in the same nerve terminal, and can be activated by
endogenous adenosine simultaneously [93,94].
Regarding synaptic transmission, A1Rs are typically inhibitory;
tonically, adenosine exerts an inhibitory effect upon hippocampal
transmission [95,96]. When A1Rs are blocked, an excitatory effect is
observed, via both the lack of A1R activation and increase in A2AR
activation. This suggests that although the net effect of endogenous
adenosine is inhibitory, it is possible to observe the activation of both
receptors under physiological concentrations of adenosine. Moreover,
preferential activation of A1R or A2AR may be regulated according to
the source of adenosine. High-frequency stimulation of neurons
induces the release of ATP, and it has been demonstrated that ATP-
derived adenosine predominantly activates excitatory A2AR [97–99].
In contrast, low-frequency stimulation leads to preferential activation
of the inhibitory A1 receptors, as a consequence of the release of
adenosine as such [97]. Interestingly in motor nerve endings of infant
rats (peri-weaning) activation of A2ARs predominates over A1Rs even
when an increase of extracellular adenosine is originated by ENT
reversal [94].
Modulation of adenosine receptors has long thought to be a useful
strategy in the treatment ofmultiple pathological states in the nervous
system, such as sleep disorders, epilepsy, stroke, pain and multiple
neurodegenerative diseases [100]. In many cases, activation of A1R or
inactivation of A2ARhas a protective role in the nervous system [88,92].
Recent epidemiological data, together with experiments in mice, have
correlated caffeine consumption, a non-speciﬁc adenosine receptor
antagonist, with decreased risk of developing AD [101,102]. Impor-
tantly, A2AR antagonists have been tested in clinical trials for the
treatment of PD. A2AR are highly abundant in the basal ganglia and
form complexes with dopamine D2 receptors, displaying reciprocal
antagonist properties. Accordingly, antagonism of adenosine A2AR is
protective in PDmodels andpotentiates the effects of L-DOPA,which is
commonly used in the treatment of this disease [103,104].
1.2.1.1. Adenosine A2A receptors. The discovery in 1992 [105] that
A2ARs, in spite of their low density distribution, facilitate synaptic
transmission in the hippocampus, raised the intriguing issue of identi-
fying their major role in this brain area (like in Pirandello's play—Sei
Personaggi in Cerca d'Autore). Out of doubt, inwhat concernsmodulation
of hippocampal synaptic transmission, the clearest inﬂuence of
adenosine is inhibitory [106], operating through A1R [107].
One of the most well-established effects of adenosine at the CNS is
its capacity to increase intracellular cyclic AMP (cAMP) levels in several
brain areas [see 108]; it was from the very beginning recognized that
cAMP enhancing actions of adenosine operate through A2 receptors
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involved in the increase of cAMP in brain slices (e.g. histamine,
norepinephrine, serotonin), causing more than additive effects on
cAMP accumulation. An interesting aspect reviewed more than
35 years ago by Daly [108] is that the accumulation in cAMP induced
by adenosine and by electrical stimulation is similar in magnitude.
Moreover, Sattin and Rall [110] demonstrated that methylxanthines
block adenosine-mediated actions, by blocking cell membrane aden-
osine receptors [111]. These xanthine-sensitive effects of adenosine,
detected more than 20 years ago, reveal the importance of the
nucleoside to regulate putative facilitatory functions in the CNS.
Although the inhibitory effects of adenosine on synaptic trans-
mission and their non-correlation with increases in cAMP levels were
described early [112,113], the investigations of the excitatory effects
of adenosine were delayed due to the unique distribution of the A2AR.
The striatum was identiﬁed as the “headquarters” of the A2AR and it
took several years to establish that the A2AR outside the striatum
could play relevant actions in neuronal cells. As we will highlight in
the remaining sections of this review, a relevant action is the ability to
trigger BDNF actions at synapses.
2. Synaptic effects of BDNF and their dependence on adenosine
A2A receptor activation
2.1. Cross-talk between adenosine A2A and TrkB receptors
The actions of GPCRs and receptor tyrosine kinases (RTKs) can be
tightly related, and to date different cross-talk mechanisms have been
proposed [114]. The effects of GPCR agonists on RTKs typically
involve: (1) facilitation/sensitization of RTKs for their cognate ligands
[47,115–118]; (2) increase of the synthesis of the endogenous RTK
ligand [119,120]; or (3) activation of RTKs in the absence of ligand, a
phenomenon called transactivation [for examples, see 121,122].
It has been shown that activation of A2AR or pituitary adenylyl
cyclase-activating polypeptide receptor 1 (PAC1), among the different
GPCR agonists tested, were able to directly activate TrkA and TrkB
receptors in the absence of NGF or BDNF (transactivation), respec-
tively [5,121]. Further studies demonstrated that transactivation of
Trk receptors by A2AR is maximal after 3 h of agonist treatment and
involves mostly immature, intracellular Trk receptors located in
Golgi-associated membranes [5,123]. Furthermore, direct activation
of Trk receptors by adenosine requires cAMP, increases in intracellular
calcium, protein synthesis and activation of Fyn, a member of the Src-
family kinases. In fact, Fyn is able to directly phosphorylate TrkB
receptors in response to adenosine, and is colocalized with intracel-
lular TrkB receptors [124]. Neurotrophin receptors can be also directly
activated by dopamine D1 receptors [125], glucocorticoids [126] and
zinc [127]. Importantly, transactivation of TrkB receptors by adeno-
sine, dopamine, glucocorticoids or zinc does not involve increased
expression of BDNF or NGF [5,125–127].
Besides inducing RTK transactivation, A2AR activation also increase
the biological effects of a RTK ligand, i.e., activation of A2ARs is able to
trigger various TrkB-mediated BDNF actions in the nervous system.
These two inﬂuences of A2ARs over RTKsmight occur on different time
spans and through different mechanisms. Below, we will mostly
discuss evidence for A2AR-induced triggering of TrkB receptors.
2.2. Basal synaptic transmission
The cross-talk between adenosine A2A and TrkB receptors has been
carefully investigated in the hippocampus. It became clear that A2AR
activation facilitates BDNF effects at synapses, and that this occurs
after a short period (30–45 min) of superfusion of A2AR receptor
agonists to hippocampal slices [47]. Incubation of neurons with the
A2AR agonist for the same short period does not induce TrkB
transactivation, i.e., TrkB phosphorylation in the absence of BDNF[5]. Interestingly, in infant (peri-weaning) rats a BDNF-induced
facilitation of basal, low-frequency-evoked excitatory synaptic trans-
mission can only be observed if A2AR are exogenously activated by an
agonist, or if adenosine release is enhanced by either a depolarization
pulse or by inhibiting adenosine kinase [47]. In contrast, in adult rats
[128] or mice [129] the levels of extracellular adenosine and of tonic
A2AR activation are enough to trigger a BDNF response. Thus, in adult
animals, exogenous application of BDNF per se is enough to facilitate
synaptic transmission, but this effect is fully lost when A2AR are
blocked, demonstrating the requirement of co-activation of A2AR by
endogenous adenosine. As pointed out [128], differences in age or in
basal levels of extracellular adenosine may therefore explain several
discrepancies in literature regarding effects of BDNF on synaptic
transmission in the hippocampus. How BDNF is delivered to cells,
namely in a sudden or gradual way, also inﬂuences BDNF signalling,
synaptic BDNF actions, and the proﬁle of BDNF-induced morpholog-
ical changes in cultured neurons, suggesting that the kinetics of TrkB
activation is critical for cell signalling and functions [130].
The mechanisms underlying the facilitatory effect of A2AR on TrkB
function involve the cAMP/protein kinase A (PKA) pathway and can be
mimicked by a previous depolarization pulse, suggesting that activity-
induced release of adenosine can physiologically have a permissive role
in the synaptic effects of BDNF [47]. Altogether, the available
information allows to conclude that the excitatory effect induced by
BDNF on synaptic transmission in the hippocampus is dependent on
TrkB and on A2AR activation, through a mechanism that requires cAMP
formation and protein kinase A (PKA) activity. This effect on excitatory
transmission at hippocampal slices may be related to glutamatergic
presynaptic actions of BDNF, since this neurotrophin facilitates
glutamate release from isolated nerve endings [42,50], an action also
dependent on A2AR activation by endogenous adenosine [6].
Motor nerve terminals also express TrkB and A2AReceptors. BDNF
facilitates transmission at developing neuromuscular junctions [1], an
action regulated by cAMP [131]. Similarly to the rat hippocampus,
depolarizing conditions and A2AR activation are required to trigger an
excitatory action of BDNF on neuromuscular transmission [132]. This
cross-talk between TrkB and A2A receptors also requires relatively short
(about 45 min) times of bath superfusion with the A2AR agonist [132],
being therefore faster than TrkB transactivation by A2AR. Activation of
A2ARs per se enhances neuromuscular transmission [93], and this
allowed to understand the hierarchy between TrkB receptors and A2ARs
to control transmitter release at motor nerve endings. Since the
excitatory action of A2AR agonists on end-plate potentials (EPPs) is
not inﬂuenced by the inhibitor of tyrosine kinases, K252a, one can
conclude that the effect of the A2AR agonist on neuromuscular
transmission does not require TrkB receptor activation [132]. Converse-
ly, the facilitatory effect of BDNFupon EPP amplitude is blockednot only
by A2AR antagonists but also by PKA inhibitors, indicating that the A2AR/
cAMP/PKA cascade is a necessary triggering signal for TrkB activation.
The conclusion that A2ARs are upstream of TrkB receptor activation is
reinforced from evidence that phospholipase C (PLC) inhibition did not
prevent the excitatory action of the A2AR agonist on neuromuscular
transmission, but abolished theactionofBDNF [132]. SinceBDNFactions
are facilitated by depolarization [1] and by cAMP [131], the sequence of
events leading to facilitation of BDNFeffects by depolarizationmight be:
a depolarization-induced raise in adenosine levels, leading to activation
of A2AR and consequent activation of the cAMP/PKA pathway (see
Fig. 1), which in turn facilitates TrkB-induced activation of its signalling
cascade, including the PLC pathway (see Fig. 1).
2.3. Long-term potentiation (LTP)
The inﬂuence of neurotrophins in the nervous system also spans to
activity-dependent forms of synaptic plasticity [133], LTP, the neuro-
physiological basis for learning and memory [134]. Most of these
actions have been seen in the hippocampus, where BDNF and TrkB
Fig. 1. Signalling cascades activated by adenosine A2A and TrkB receptors. Adenosine A2AR are mainly implicated in the activation of Gs proteins and the cAMP/PKA signalling
pathway. TrkB receptors predominantly signal through the activation of PLCγ, Akt and MAPK pathways. As schematized in the ﬁgure, the presence of common signalling
intermediates downstream A2A and TrkB receptors might account for the facilitatory action of adenosine A2AR activation upon TrkB-mediated effects. Activation of A2AR also
induces translocation of TrkB receptors to lipid rafts. TrkB localization in these membrane microdomains is important for BDNF actions and may be involved in the modulation
of TrkB-mediated signalling cascades by A2AR. Abbreviations: AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; Cdc42, cell division control protein 42 homolog;
CREB, cAMP response element binding protein; DAG, diacylglycerol; Epac, exchange protein activated by cAMP; Erk 1/2-extracellular signal-regulated protein kinases; Grb2, growth
factor receptor-bound protein 2; IP3, inositol 1,4,5-trisphosphate; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase 1/2; PI3K,
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, Phospholipase C; PKA, Protein kinase A; Rac1, Ras-related C3 botulinum toxin substrate 1; Ras,
small GTP-binding protein Ras; SOS, son of sevenless.
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that hippocampal LTP is strongly impaired in both BDNF [52,53] and
TrkB [137,138] knockout mice, a deﬁcit that could be rescued by
adenoviral-mediated (re)expression of BDNF [139], or even by
administration of exogenous BDNF [53]. Extracellular adenosine also
plays an important role in the modulation of synaptic plasticity, and
can both decrease (A1R-mediated) and increase (A2AR-mediated)
synaptic plasticity events [140].
As previously mentioned, BDNF expression and release [141,142],
as well as release of adenosine [2] and of its precursor ATP [99], are
much more pronounced upon depolarization and during physiolog-
ically relevant patterns of neuronal activity, namely those that induce
hippocampal LTP. Therefore, high neuronal activity seems to create
ideal physiological conditions for the interplay between A2A and TrkB
receptors to take place. We were able to clearly show that BDNF
facilitatory effects upon LTP are completely dependent on A2AR
activation by endogenous adenosine and that this process requires
active PKA [117]. This clearly identiﬁes adenosine as an endogenous
“gate” that unravels BDNF actions upon LTP, and adds a new
physiologic partner to the TrkB signalling process that inﬂuences
synaptic plasticity phenomena. Remarkably, cAMP was also proposed
to function as a gating signal that enables BDNF modulation of
synaptic plasticity [see 11]. Indeed, the cAMP/PKA pathway is not adownstream effector in the BDNF/TrkB signaling cascade [143], but
neuronal activity increases the local intracellular concentration of
cAMP [144], which may facilitate BDNF actions either by facilitating
the trafﬁcking of TrkB receptors into active sites at synapses and/or by
facilitating BDNF-induced TrkB phosphorylation [145]. Since A2AR
activation enhances the adenylate cyclase/cAMP/PKA signalling
pathway [see 146], the increase in cAMP levels may be a key pivot
to relate the inﬂuence of adenosine, A2ARs, high neuronal frequency
rate, and BDNF upon synaptic plasticity. Interestingly, endogenous
activation of adenosine A2ARs plays a pivotal effect on the associative
learning process and its relevant hippocampal circuits, including
activity-dependent long-lasting changes at the CA3-CA1 synapse
[147]. It remains to be established if this loss of synaptic plasticity and
concomitant associative learning induced by A2AR blockade in vivo
results from impairment of BDNF signalling. It may well be so because
TrkB receptors modulate speciﬁc phases of conditional learning and
synaptic plasticity recorded concomitantly [148].
2.4. Postsynaptic modulation of cholinergic transmission in the
hippocampus
Neuronal nicotinic acetylcholine receptors (nAChRs) are widely
expressed in the brain. The homopentameric α7 subtype of nAChR, in
1345A.M. Sebastião et al. / Biochimica et Biophysica Acta 1808 (2011) 1340–1349particular, has determinant actions in the hippocampus by supplying
calcium signals that depolarize cells and inﬂuence several calcium-
dependent events, including transmitter release and plasticity [149–
152]. Recent evidence has established that BDNF leads to an increase
in α7nAChR number and clustering over a time course of several
hours to days [153–155]. In contrast, BDNF induces a fast (maximal
effect within less than 60 min) decrease of α7nAChR-mediated
responses in hippocampal interneurons of the CA1 stratum radiatum
[15]. Such inhibitory effect of BDNF involves the actin cytoskeleton
and occurs through TrkB-mediated activation of the phospholipase C
(PLC)/protein kinase C (PKC) pathway, requiring Ca2+ ions as a
cofactor [15]. Additionally, constitutively released adenosine, acting
on A2AR, is required to gate the action of BDNF [15]. Although
corroborating several evidences on the tight relationship between
tyrosine kinase TrkB and adenosine A2AR, this set of results contrasts
with BDNF-induced modulation of synaptic inputs to pyramidal cells,
which in rats of similar age (peri-weaning) requires exogenous
activation of A2AR [47]. In both cases, however, the action of BDNF is
lost if A2AR are blocked. It is thus possible that adenosine levels are
greater in the vicinity of interneurons or, alternatively, that inter-
neurons might exhibit an increased sensitivity for the basal levels of
adenosine. In fact, both possibilities are consistentwith several reports
showing that extracellular adenosine levels affect interneurons in a
more powerful manner than pyramidal cells [156,157].
It remains to be investigated which signalling cascades are
involved in the long-term effect of BDNF upon the expression of
α7nAChRs [155] and whether this effect is correlated with functional
long lasting enhancement of nicotinic responses [154]. The fast
inhibition ofα7nAChR-mediated responses by BDNF can bemimicked
by direct activation of PKC with phorbol esters [15]. Interestingly,
there are no predicted consensus sequences for PKC phosphorylation
in the intracellular domains of α7 subunits [158,159]. Thus, as it has
been pointed out [15], it is possible that the acute inhibitory effect of
BDNF onα7nAChR function involve the regulation of phosphorylation
of intermediate proteins that regulate trafﬁcking, clustering, and/or
lateral diffusion of the receptors.
2.5. BDNF and GABA
GABA activity at synapses is ended by rapid reuptake through
speciﬁc neuronal and astrocytic GABA transporters, which are regulated
by several signalling cascades that include kinases and phosphatases
[160]. The number of functional GABA transporters (GAT-1) in cultured
neurons is increased by BDNF [161]. Interestingly, BDNF inhibits GABA
transport at isolated nerve endings, an action observed either when
transport is inward [162] or reversed in the outward direction [42]. One
should keep in mind that both actions of BDNF might contribute to a
facilitation of GABAergic tonus since an inhibition of GABA transport at
the nerve endings may lead to an increase in the amounts of synaptic
GABA, whereas an increase in GABA transport in other neuronal
membrane compartments may rescue GABA to replenish the releasable
pool. The molecular mechanisms that underlie the different ways BDNF
uses todifferentiallymodulateGAT-1 atnerve endings or entireneurons
is not entirely understood yet, but the evidence so far available points
towards the involvement of different signalling cascades, with PLCγ
involvement into the inhibition at nerve endings [51], but not in
cultured neurons [161,163].
Interestingly, the effect of BDNF on synaptosomal GABA uptake
was not appreciably affected by A2AR blockade or removal of
endogenous adenosine with adenosine deaminase, suggesting that
A2AR co-activation is not an essential step for this action of BDNF. This
contrasts with the facilitatory action of BDNF on excitatory synaptic
transmission [47,132], where A2AR blockade fully prevents the action of
BDNF. However, in spite of not being essential, exogenously added A2AR
agonists are able to enhanceBDNF-induced inhibitionofGAT-1 transport
at nerve endings, an effect prevented by A2AR antagonists [163].BDNF has been shown to rapidly modulate GABAergic transmis-
sion in the hippocampus through pre- and postsynaptic mechanisms,
but it is still not known how these actions are affected by adenosine
A2A receptors. Presynaptically, a decrease in GABAergic input to
glutamatergic neurones has been reported [43]. Postsynaptically,
BDNF decreases GABAergic transmission to pyramidal neurones [44],
inducing a rapid downregulation of GABAA receptor surface expres-
sion [164]. Interestingly, in immature neurons BDNF enhances, rather
than inhibits, GABA release, and this is part of a positive feedback loop
between GABA and BDNF expression [165]. Since GAT-1 mediated
transport in nerve terminals appears to contribute to the maturation
of point-to-point GABAergic synapses [see 166], a ﬁne control of
GABAergic transmission that simultaneously involves BDNF and GAT-
1 may be particularly relevant in the shaping GABAergic synapses
under maturation, and it would be highly interesting to know
whether adenosine A2A receptors play any role in this process.
2.6. Trophic effects of BDNF and adenosine A2AR
BDNF is involved in neuronal maturation [see e.g. 167], an effect
regulated by cAMP [145]; therefore, one could anticipate that this
action of BDNF could be inﬂuenced by activation of A2AR. However,
A2AR agonists do not seem to inﬂuence the actions of BDNF on neurite
outgrowth in cortical neurons [168]. Nevertheless A2ARs can rescue
neurite outgrowth impairment caused by interference with the NGF
signalling cascade in PC12 cells [169] as well as to promote PC12 cell
survival upon NGF withdrawal [5].
2.7. Lipid raft localization of TrkB receptors as a mechanism to trigger
BDNF effects on synaptic transmission
Lipid rafts are membrane microdomains enriched in cholesterol,
glicosphingolipids and speciﬁc proteins. Convincing proteomic data
have been reinforcing the role of lipid rafts as coordinators of signal
transduction; for example, receptors inside lipid rafts may activate
distinct signalling cascades from receptors localized outside rafts
[170].
There is now evidence that lipid rafts are essential for BDNF
signalling, and both TrkB and p75NTR receptors can be located in these
membrane domains [171–173]. Translocation of TrkB receptors to
lipid rafts is regulated by BDNF, and this movement of receptors is
required for its effects on glutamate release, synaptic fatigue [173] and
for activation of the PLC pathway [174]. It is also of interest to note
that BDNF itself enhances cholesterol biosynthesis, which results in
higher levels of presynaptic proteins in lipid rafts and proper synapse
development [175].
The localization of adenosine A2AR in lipid rafts is still mostly
unknown. In a recent study, using A2A-overexpressing PC12 cells, it
was suggested that A2AR-induced adenylate cyclase activation is
dependent on the cholesterol levels of the membrane, while A2A-
induced MAPK activation was not affected by lipid raft disruption
[176]. Additionally, it was suggested that A2AR localize in lipid raft
domains of motor neurons, where A2AR physically interact with Fyn
and TrkB receptors [177].
2.7.1. Role of lipid rafts in A2A-TrkB receptor signalling
Recent evidence has shown that activation of A2AR increases the
levels of TrkB receptors in lipid rafts and potentiates BDNF-induced
TrkB phosphorylation in these membrane microdomains [6]. Al-
though both A2AR and TrkB receptor activation promote translocation
of TrkB receptors to lipid rafts, the mechanisms used by A2AR agonists
are different from those used by BDNF, and involve cAMP and Src-
family kinase activation (see Fig. 1). Fyn, a member of the Src-family
kinases, is a good candidate for mediating A2A-induced TrkB
translocation to lipid rafts, since it can be activated by A2A agonists
and is required for TrkB localization in lipid rafts [124,174].
Fig. 2. Schematic representation of cross-talk between TrkB and A2AR, where it
highlighted the dependence of A2AR activation for BDNF actions on the nervous system.
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and synaptic plasticity [6], require both lipid raft integrity and A2AR
activation, probably due to an activity-dependent recruitment of TrkB
receptors to lipid rafts. Interestingly, high-frequency stimulation of
hippocampal slices resulted in a higher density of TrkB receptors in
lipid rafts, an effect totally abolished when endogenous extracellular
adenosine is removed [6]. To our knowledge, this is the unique
demonstration of an activity-dependent recruitment of TrkB receptors
to lipid rafts, and notably, this recruitment is fully dependent upon the
presence of extracellular adenosine. As previously discussed, the
levels of extracellular adenosine increase and A2AR activation are
favoured after high-frequency neuronal ﬁring [for a review, see 178].
Therefore, adenosine A2AR-induced translocation of TrkB receptors to
lipid rafts may be a link through which adenosine A2A and TrkB
receptors act as coincident detectors of high frequency neuronal ﬁring
and amplify excitatory synaptic transmission [6].
3. Potential therapeutic interest of the cross-talk between A2AR
and TrkB receptors in neurodegenerative diseases
Enhancement of neurotrophic-like effects might be desirable to
delay the progression of some neurodegenerative diseases, where lack
neurotrophic factors may be a direct or indirect cause of exacerbated
neuronal death [for a review, see 179]. Indeed, the knowledge of the
regulatory actions of neurotrophic factors in neuronal functions and in
response to neuronal injury, together with the evidence that changes in
BDNF signalling are associated with a wide variety of pathologies (see
Section 1.1.3), triggered in the past decade a number of clinical trials
involving the use of BDNF for neurodegenerative disorders such as
amyotrophic lateral sclerosis and diabetic neuropathy. However, BDNF
had minimal beneﬁcial effects and produced side effects such as pain
and gastrointestinal symptoms [180]. Furthermore, major problems
related to BDNF-based therapies are the half-life of this peptide in the
bloodstream as well as its the inability to cross the blood brain barrier;
these problems have limited the possibility of using BDNF as a non-
invasive and effective treatment for neurological disorders [181].
Therefore, the lack of controlled levels of BDNF at the site of action
and the presence of endogenous compensative processes that may
regulate BDNF levels in the brain, may have contributed to some
negative results in clinical trials. An approach that could circumvent
some of the above-mentioned difﬁculties would be modulation of
neurotrophin receptor signallingwith the use of smallmolecules,which
may be considerably cheaper, less invasive andmore feasible in terms of
molecule design [181,182]. Therefore, adenosine A2AR agonists may
prove useful in a near future as promoters of neurotrophic-like effects in
the nervous system.Ofhigh relevance in this context is the report that in
a HD mouse model that involves genetic mutation of Huntingtin,
therefore most probably, a reduction of striatal BDNF levels, daily
administration of an A2AR agonist delays progressive deterioration of
motor performance and huntingtin aggregation [183]. In the same
mousemodel, i.p. administration of the A2A receptor agonist for 3 weeks
induces changes in the subunit composition of NMDA receptors
compatible with a decreased susceptibility to excitotoxicity [184];
interestingly this action was speciﬁc for the striatum and for the HD
mice [184], highly suggestive of an A2A receptor mediated neuroprotec-
tion selective for BDNF deﬁcient HD pathology.
4. Concluding remarks
A summary of the main data obtained on A2A-BDNF interactions is
presented in Fig. 2, wherewe can see that A2AR activation is required for
the BDNF effects on synaptic transmission and LTP in the hippocampus,
and on transmission at the neuromuscular junction. A2AR activation is
dispensable in the case of BDNF effects on GABA uptake and also on
actions of BDNF upon neuronal branching. These differencesmay reside
upon the mechanisms required for each speciﬁc BDNF action. It ispossible that acutely triggering of neurotrophic factor actions through
adenosine receptors results from a requirement of fast translocation of
Trk receptors to lipid rafts, which may wake up the remaining “silent”
neurotrophin receptors at synapses.
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